公開(公告)號
|
CN1656089A
|
公開(公告)日
|
2005.08.17
|
申請(專利)號
|
CN03812198.0
|
申請日期
|
2003.05.22
|
專利名稱
|
苯基-噻吩型維生素D受體調(diào)節(jié)劑
|
主分類號
|
C07D333/38
|
分類號
|
C07D333/38;C07D333/16;C07D333/18;C07D333/22;C07D409/12;C07D409/06;C07D333/34;C07D413/04;C07D409/04;A61K31/381;A61K31/401;A61K31/41;A61K31/4245;A61P19/10
|
分案原申請?zhí)? |
|
優(yōu)先權(quán)
|
2002.5.29 US 60/384,151
|
申請(專利權(quán))人
|
伊萊利利公司
|
發(fā)明(設(shè)計)人
|
K·R·達(dá)恩克;R·P·加朱斯基;C·D·瓊斯;J·H·萊恩巴格;陸建良;馬天偉;S·納帕爾;T·P·西馬德;余迎廣;E·E·布涅爾;R·E·斯蒂特斯
|
地址
|
美國印第安納州
|
頒證日
|
|
國際申請
|
PCT/US2003/014539 2003.5.22
|
進(jìn)入國家日期
|
2004.11.29
|
專利代理機(jī)構(gòu)
|
中國專利代理(香港)有限公司
|
代理人
|
溫宏艷;李連濤
|
國省代碼
|
美國;US
|
主權(quán)項
|
式I表示的化合物或其藥學(xué)上可接受的鹽或其前藥衍生物:其中:R和R′獨(dú)立地是C1-C5烷基、C1-C5氟烷基,或者R和R′一起形成取代或未取代的、飽和或不飽和的具有3-8個碳原子的碳環(huán);環(huán)原子Q1和Q2獨(dú)立地選自碳或硫,條件是一個原子是硫,另一個原子是碳;Rp和RT獨(dú)立地選自氫、鹵素、C1-C5烷基、C1-C5氟烷基、-O-C1-C5烷基、-S-C1-C5烷基、-O-C1-C5氟烷基、-CN、-NO2、乙;-S-C1-C5氟烷基、C2-C5鏈烯基、C3-C5環(huán)烷基和C3-C5環(huán)烯基;(Lp)和(LT)是二價連接基團(tuán),其獨(dú)立地選自下列基團(tuán):一條鍵,-(CH2)m-O-,-(CH2)m-S-,-(CH2)m-S(O)-,-(CH2)m-S(O)2-,-(CH2)m-C≡C-,-(CH2)m-C=C-,-SO2-NH-,-SO2-O-,-NH-S(O)-,-CH2-S(O)-,-O-S(O)-,其中m是0、1或2,X1是氧或硫,每個R40獨(dú)立地是氫或C1-C5烷基或C1-C5氟烷基;Zp和ZT獨(dú)立地選自:-氫,-苯基-芐基,-氟苯基-(C1-C5烷基),-(C2-C5鏈烯基),-(C3-C5環(huán)烷基),-(C3-C5環(huán)烯基),-(C1-C5羥基烷基),-(C1-C5氟烷基),-(C1-C5烷基)-苯基,-(C1-C5烷基)-O-(C1-C5)烷基,-(C1-C5烷基)-NH2,-(C1-C5烷基)-NH-(C1-C5烷基),-(C1-C5烷基)-N-(C1-C5烷基)2,-(C1-C5烷基)-C(O)-NH2,-(C1-C5烷基)-C(O)-NH-(C1-C5烷基),-(C1-C5烷基)-C(O)-N-(C1-C5烷基)2,-(C1-C5烷基)-C(O)-(C1-C5烷基),-(C1-C5烷基)-NH-SO2-(C1-C5烷基),-(C1-C5烷基)-N-吡咯烷-2-酮,-(C1-C5烷基)-N-吡咯烷,-(C1-C5烷基)-(1-甲基吡咯烷-2-酮-3-基),-(C1-C5烷基)-C(O)-(O-C1-C5烷基),-(C1-C5烷基)-C(O)-OH,-(C1-C5烷基)-5-四唑基,-(C1-C5烷基)-P(O)-(O-C1-C5烷基)2,-(C1-C5烷基)-SO2-(C1-C5烷基),-(C1-C5烷基)-SO2-NH2,-(C1-C5烷基)-SO2-NH-(C1-C5烷基),-(C1-C5烷基)-SO2-N-(C1-C5烷基)2,-(C1-C5烷基)-SO2-(C1-C5烷基),-(C1-C5烷基)-S(O)-(C1-C5烷基),-(C1-C5烷基)-S(O)-NH2,-(C1-C5烷基)-S(O)-NH-(C1-C5烷基),-(C1-C5烷基)-S(O)-N-(C1-C5烷基)2,-(C1-C5烷基)-S(O)-(C1-C5烷基),-(C1-C5烷基)-N(C(O)(C1-C5烷基)CH2C(O)OH,-(C1-C5烷基)-N(C(O)(C1-C5烷基)CH2C(O)-(C1-C5烷基),-CH(OH)-(C1-C5烷基)-CH(OH)-(C2-C5鏈烯基),-CH(OH)-(C3-C5環(huán)烷基),-CH(OH)-(C3-C5環(huán)烯基),-CH(OH)-(C1-C5羥基烷基),-CH(OH)-(C1-C5氟烷基),-CH(OH)-苯基-CH(OH)-5-四唑基,-CH(OH)-(1-甲基吡咯烷-2-酮-3-基),-C(O)-(C1-C5烷基),-C(O)-(C1-C5烷基)-C(O)OH,-C(O)-(C1-C5烷基)-C(O)(O-C1-C5烷基),-C(O)-(C2-C5鏈烯基),-C(O)-(C3-C5環(huán)烷基),-C(O)-(C3-C5環(huán)烯基),-C(O)-(C1-C5羥基烷基),-C(O)-(C1-C5氟烷基),-C(O)-(C1-C5烷基)-苯基-C(O)-O-(C1-C5烷基),-C(O)-O-(C2-C5鏈烯基),-C(O)-O-(C3-C5環(huán)烷基),-C(O)-O-(C3-C5環(huán)烯基),-C(O)-O-(C1-C5羥基烷基),-C(O)-O-(C1-C5氟烷基),-C(O)-O-(C1-C5烷基)-苯基,-C(O)-NH2,-C(O)-NH(OH),-C(O)-NH-(C1-C5烷基),-C(O)-N-(C1-C5烷基)2,-C(O)-NH-(C2-C5鏈烯基),-C(O)-NH-(C3-C5環(huán)烷基),-C(O)-NH-(C3-C5環(huán)烯基),-C(O)-NH-(C1-C5氟烷基),-C(O)-NH-(C1-C5烷基)-苯基,-C(O)-NH-SO2-(C1-C5烷基),-C(O)-NH-SO2-(C2-C5鏈烯基),-C(O)-NH-SO2-(C3-C5環(huán)烷基),-C(O)-NH-SO2-(C3-C5環(huán)烯基),-C(O)-NH-S(O)-(C1-C5烷基),-C(O)-NH-S(O)-(C2-C5鏈烯基),-C(O)-NH-S(O)-(C3-C5環(huán)烷基),-C(O)-NH-S(O)-(C3-C5環(huán)烯基),-C(O)-NH-(C1-C5氟烷基),-C(O)-NH-(C1-C5烷基)-苯基-C(O)-NH-(C1-C5烷基)-SO2-(C1-C5烷基),-C(O)-NH-(C1-C5烷基)-S(O)-(C1-C5烷基),-C(O)-NH-CH2-C(O)OH-C(O)-NH-CH2-C(O)-(O-C1-C5烷基),-C(O)-N-(C1-C5烷基)(C(O)OH),-C(O)-N-(C1-C5烷基)(C(O)-(O-C1-C5烷基)),-C(O)-NH-CH((CH2)(CO2H))(CO2H),-C(O)-NH-CH((CH2)(C(O)-(C1-C5烷基)))(C(O)-(O-C1-C5烷基)),-C(O)-NH-CH((CH2OH)(CO2H)),-C(O)-NH-CH((CH2OH)(C(O)(O-C1-C5烷基)),-C(O)-NH-C((C1-C5烷基)(C1-C5烷基))(CO2H),-C(O)-NH-C((C1-C5烷基)(C1-C5烷基))(C(O)-(O-C1-C5烷基)),-C(O)-NH-5-四唑基,-C(O)-N-吡咯烷-2-酮,-C(O)-N-吡咯烷,-C(O)-(1-甲基吡咯烷-2-酮-3-基),-C(O)-(C1-C5烷基)-N-吡咯烷-2-酮,-C(O)-(C1-C5烷基)-N-吡咯烷,-C(O)-(C1-C5烷基)-(1-甲基吡咯烷-2-酮-3-基),-C(O)-N-吡咯烷-2-(CO2H),-C(O)-N-吡咯烷-2-(C(O)-(O-C1-C5烷基)),-C(O)-N-(C(O)-(C1-C5烷基))CH2)(CO2H),-C(O)-N-(C(O)-(C1-C5烷基))CH2)(C(O)-(O-C1-C5烷基)),-C(O)-N-(C1-C5烷基))CH2(CO2H),-C(O)-C(O)-OH,-C(O)-C(O)-(C1-C5烷基),-C(O)-C(O)-(C2-C5鏈烯基),-C(O)-C(O)-(C3-C5環(huán)烷基),-C(O)-C(O)-(C3-C5環(huán)烯基1),-C(O)-C(O)-(C1-C5羥基烷基1),-C(O)-C(O)-(C1-C5氟烷基),-C(O)-C(O)-(C1-C5烷基)-苯基,-C(O)-C(O)-NH2,-C(O)-C(O)-NH-(C1-C5烷基),-C(O)-C(O)-N-(C1-C5烷基)2,-C(O)-C(O)-5-四唑基,-C(O)-C(O)-N-吡咯烷-2-酮,-C(O)-C(O)-N-吡咯烷,-C(O)-C(O)-(1-甲基吡咯烷-2-酮-3-基),-O-(C1-C5烷基),-O-(C2-C5鏈烯基),-O-(C3-C5環(huán)烷基),-O-(C3-C5環(huán)烯基),-O-(C
|
摘要
|
本發(fā)明涉及新的、非-斷甾族的、具有維生素D受體(VDR)調(diào)節(jié)活性的苯基-噻吩化合物,與1α,25二羥基維生素D3相比,具有較低的高鈣血。這些化合物用于治療骨骼疾病和牛皮癬。
|
國際公布
|
WO2003/101978 英 2003.12.11
|